{"id":61,"date":"2022-11-28T20:54:11","date_gmt":"2022-11-28T20:54:11","guid":{"rendered":"https:\/\/voxzogohcp-dev-001.azurewebsites.net\/en-us\/voxzogo\/?page_id=61"},"modified":"2024-11-14T01:18:23","modified_gmt":"2024-11-14T01:18:23","slug":"voxzogo-safety","status":"publish","type":"page","link":"https:\/\/www.voxzogo.com\/en-us\/voxzogo-safety\/","title":{"rendered":"VOXZOGO Safety"},"content":{"rendered":"
This table shows the number (n) of patients who experienced the most common side effects seen in more than 10% of VOXZOGO® (vosoritide) patients over 1 year in a clinical trial*<\/p>\n <\/div>\n\n *Includes adverse reactions occurring in over 10% of VOXZOGO patients and more frequently in the VOXZOGO arm with a risk difference of ≥5% (ie, difference of >2 subjects) between treatment arms. The most common side effects seen in over 10% of VOXZOGO®<\/sup> (vosoritide) patients under 5 years of age were injection site reactions (86%) and rash (28%).<\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n §<\/sup>1 child discontinued due to injection pain, and 1 child discontinued due to fear of needles.<\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n
<\/div>\n <\/figure>\n\n
\n†<\/sup>Injection site reactions occurring more frequently in VOXZOGO-treated subjects than placebo.
\n‡<\/sup>Includes the preferred terms: gastroenteritis and gastroenteritis, viral.<\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\nThe overall safety profile of VOXZOGO in children under the age of 5 was similar to that seen in children aged 5 and up.<\/h2>\n
97% of children aged 5 to 15 (58\/60) continued to take VOXZOGO after 1 year§<\/sup><\/h2>\n <\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n
Learn more about how to give VOXZOGO to your child.<\/h4>\n